Ryan Scott

Articles

Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC

November 16th 2023

China’s National Medical Products Administration has granted conditional marketing approval to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Pembrolizumab Plus Enzalutamide/ADT Fails to Improve rPFS in mHSPC

November 15th 2023

The addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) and androgen deprivation therapy did not improve radiographic progression-free survival vs placebo plus enzalutamide and ADT in patients with metastatic hormone-sensitive prostate cancer, according to data from the phase 3 KEYNOTE-991 trial presented at the 2023 ESMO Congress.

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15th 2023

The FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an announcement from Rznomics Inc.

Case Study Highlights Uncommon Skin Rash as Possible Sign of Lung Cancer Recurrence

November 13th 2023

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

Research Remains Focused on Bringing CAR T-Cell Therapy to Solid Tumors

November 7th 2023

Mark Leick, MD, discusses how the emergence of CAR T-cell therapies have affected the treatment paradigms in various hematologic malignancies, expands on how persisting challenges with the use of this type of treatment are being addressed, and details research into the use of CAR T-cell therapy in patients with solid tumors.

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

November 4th 2023

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.

Genomics Help Drive Active Surveillance Decisions in Low-Risk Prostate Cancer

November 3rd 2023

David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.

FDA Awards Orphan Drug Designation to Rhenium Obisbemeda in Breast Cancer With Leptomeningeal Metastases

November 3rd 2023

The FDA has granted an orphan drug designation to rhenium obisbemeda as a potential therapeutic option for patients with breast cancer and leptomeningeal metastases.

Ongoing Research Aims to Enhance Radiotherapy Techniques in Prostate Cancer

November 2nd 2023

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

VIC-1911 With/Without Sotorasib Under Investigation in KRAS G12C Inhibitor–Resistant and –Naïve NSCLC

November 2nd 2023

Sarah Goldberg, MD, MPH, highlights the mechanism of action of VIC-1911, expands on its ongoing investigation in the phase 1 trial, and sheds light on next steps planned for the agent’s investigation in KRAS G12C–mutant non–small cell lung cancer.

Exploratory Analyses Show Trastuzumab Deruxtecan Elicits Consistent Intracranial Responses in HER2-Mutated NSCLC With Brain Metastases

October 27th 2023

Pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials showed that different doses of fam-trastuzumab deruxtecan-nxki elicited similar intracranial responses in patients with HER2-mutated non–small cell lung cancer who had treated or untreated brain metastases at baseline.

Patient and Disease Characteristics Serve as Key Factors Behind Treatment Considerations in Advanced RCC

October 26th 2023

Vitaly Margulis, MD, expands on the factors to consider when treating patients with advanced RCC and how these could help inform the selection of immunotherapy-based combinations in the frontline setting.

Retrospective Data Show Venetoclax-Based Approaches Improve Outcomes in CLL/SLL After Covalent BTK Inhibitor Intolerance

October 26th 2023

Catherine C. Coombs, MD, discusses a real-world investigation of switching to a BCL-2 inhibitor-based regimen vs another covalent BTK inhibitor in patients with chronic lymphocytic leukemia/small lymphocytic leukemia who were intolerant to a prior covalent BTK inhibitor and highlighted factors to consider when deciding between these 2 approaches for this patient population.

Venetoclax Monotherapy Leads to Responses, Genomic Changes in R/R CLL

October 25th 2023

Jennifer A. Woyach, MD, elucidates the updated results generated from a phase 2 study of venetoclax monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) whose disease progressed on a prior B-cell receptor inhibitor, expanded on key findings from a genomic analysis from the study, and highlighted what these findings could mean for the CLL treatment paradigm.

Novel Bispecific Antibody EX103 Demonstrates Safety, Elicits Preliminary Antitumor Activity in R/R B-Cell NHL

October 23rd 2023

The novel CD20xCD3 bispecific antibody EX103 displayed a favorable safety profile and produced preliminary antitumor activity in heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Trastuzumab Deruxtecan Has Clinically Meaningful Activity in Solid Tumors Harboring HER2 Mutations

October 22nd 2023

Fam-trastuzumab deruxtecan-nxki elicited responses that proved to be durable in patients with a range of solid tumors harboring HER2 mutations.

Frontline Pembrolizumab Plus Trastuzumab/Chemotherapy Improves PFS in HER2+ Gastric/GEJ Cancer

October 20th 2023

The addition of pembrolizumab to combination of trastuzumab and chemotherapy led to an improvement in progression-free survival vs placebo plus trastuzumab and chemotherapy in the first-line treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction cancer, particularly in those whose tumors had a PD-L1 combined positive score.

Data Continue to Support Triplet Therapy With ADT, AR-Targeted Therapy, and Chemotherapy in mHSPC

October 18th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.

De-Escalation of Therapy Remains a Focus for Early-Stage HER2+ Breast Cancer

October 17th 2023

Francisco Javier Esteva, MD, PhD, discusses the management of early-stage HER2-positive breast cancer with a focus on de-escalation strategies, emphasizes the ongoing efforts to de-escalate chemotherapy without compromising effective treatments, and expands on the ongoing debate regarding the role of carboplatin in this setting.

Experience Helps Guide ILD Prevention/Management With Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 17th 2023

Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.